Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
Data from the BFORE study showed significantly higher 12-month major molecular remission and complete cytogenetic response with bosutinib.
All articles by Alexander M. Castellino, PhD
Momelotinib for Previously Treated Patients With Myelofibrosis
For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.
Dabrafenib Plus Trametinib Promising in Melanoma
Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).
Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer
An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.
Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer
Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.
Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.
Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases
Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.
Establishing a Short-term Response Endpoint for mCRPC Trials
After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.
Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...